[144] Labcorp Holdings Inc. SEC Filing
Labcorp Holdings Inc. insider notice reports a proposed sale of 5,643 common shares for an aggregate market value of $1,505,439.54, to be executed through Fidelity Brokerage Services on the NYSE with an approximate sale date of 08/11/2025. The shares were acquired on 03/30/2023 by restricted stock vesting as compensation. The filing also shows the seller previously sold 6,105 shares on 05/12/2025 for gross proceeds of $1,518,496.65. The issuer's total outstanding common shares are reported as 83,100,000. By signing, the seller represents no undisclosed material adverse information and notes the compliance statements relevant to Rule 144 and Rule 10b5-1.
Labcorp Holdings Inc. comunica, tramite un avviso interno, la proposta di vendita di 5,643 azioni ordinarie per un valore di mercato complessivo di $1,505,439.54, da eseguirsi tramite Fidelity Brokerage Services sulla NYSE con data di vendita approssimativa 08/11/2025. Le azioni sono state acquisite il 03/30/2023 mediante vesting di azioni ristrette come compenso. La pratica segnala inoltre che il venditore aveva precedentemente venduto 6,105 azioni il 05/12/2025 per proventi lordi di $1,518,496.65. Il numero totale di azioni ordinarie in circolazione dell'emittente 猫 riportato pari a 83,100,000. Con la firma, il venditore dichiara l'assenza di informazioni materiali avverse non divulgate e indica le dichiarazioni di conformit脿 relative alla Rule 144 e alla Rule 10b5-1.
Labcorp Holdings Inc. informa en un aviso de insider sobre la propuesta de venta de 5,643 acciones ordinarias por un valor de mercado agregado de $1,505,439.54, que se ejecutar铆a a trav茅s de Fidelity Brokerage Services en la NYSE con fecha aproximada de venta 08/11/2025. Las acciones fueron adquiridas el 03/30/2023 mediante vesting de acciones restringidas como compensaci贸n. La presentaci贸n tambi茅n muestra que el vendedor vendi贸 previamente 6,105 acciones el 05/12/2025 por ingresos brutos de $1,518,496.65. Las acciones ordinarias totales en circulaci贸n del emisor se reportan en 83,100,000. Al firmar, el vendedor declara que no existe informaci贸n material adversa no divulgada y se帽ala las declaraciones de cumplimiento relevantes a la Rule 144 y la Rule 10b5-1.
Labcorp Holdings Inc. 雮措秬鞛� 瓿奠嫓鞐� 霐半ゴ氅�, 齑� 鞁滉皜 鞎� $1,505,439.54 靸侂嫻鞚� 氤错喌欤� 5,643欤�毳� NYSE鞚� Fidelity Brokerage Services毳� 韱淀暣 08/11/2025搿� 鞓堨爼霅� 雽�霝奠爜鞚� 毵る弰鞚检棎 毵り皝頃� 鞓堨爼鞚措澕瓿� 氤搓碃頄堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� 03/30/2023鞐� 氤挫垬搿滌劀 鞝滍暅欤检嫕 氩犾姢韺�(restricted stock vesting)鞚� 韱淀暣 旆摑霅橃棃鞀惦媹雼�. 鞝滌稖靹滊鞐愲姅 霕愴暅 韺愲Г鞛愱皜 鞚挫爠鞐� 05/12/2025鞐� 6,105欤�毳� 毵り皝頃橃棳 齑濎垬鞚� $1,518,496.65鞚� 鞏混棃雼り碃 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氚滍枆須岇偓鞚� 齑� 氚滍枆 氤错喌欤� 靾橂姅 83,100,000鞙茧 氤搓碃霅╇媹雼�. 靹滊獏頃溂搿滌崹 韺愲Г鞛愲姅 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 歆勳垹頃橁碃 Rule 144 氚� Rule 10b5-1 甏�霠� 欷�靾� 歆勳垹鞚� 氇呾嫓頃╇媹雼�.
Labcorp Holdings Inc. signale, dans un avis d'initi茅, une vente propos茅e de 5,643 actions ordinaires pour une valeur marchande totale de $1,505,439.54, devant 锚tre ex茅cut茅e via Fidelity Brokerage Services 脿 la NYSE avec une date de vente approximative le 08/11/2025. Les actions ont 茅t茅 acquises le 03/30/2023 par vesting d'actions restreintes en tant que r茅mun茅ration. Le dossier indique 茅galement que le vendeur avait pr茅c茅demment c茅d茅 6,105 actions le 05/12/2025 pour un produit brut de $1,518,496.65. Le nombre total d'actions ordinaires en circulation de l'茅metteur est indiqu茅 脿 83,100,000. En signant, le vendeur d茅clare l'absence d'informations d茅favorables significatives non divulgu茅es et mentionne les d茅clarations de conformit茅 pertinentes 脿 la Rule 144 et 脿 la Rule 10b5-1.
Labcorp Holdings Inc. meldet in einer Insider-Mitteilung den geplanten Verkauf von 5,643 Stammaktien mit einem Gesamtmarktwert von $1,505,439.54, der 眉ber Fidelity Brokerage Services an der NYSE mit einem ungef盲hren Verkaufsdatum 08/11/2025 ausgef眉hrt werden soll. Die Aktien wurden am 03/30/2023 durch Restricted-Stock-Vesting als Verg眉tung erworben. Die Einreichung zeigt au脽erdem, dass der Verk盲ufer zuvor am 05/12/2025 6,105 Aktien f眉r Bruttoerl枚se von $1,518,496.65 verkauft hatte. Die insgesamt ausstehenden Stammaktien des Emittenten werden mit 83,100,000 angegeben. Mit seiner Unterschrift erkl盲rt der Verk盲ufer, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen, und verweist auf die Compliance-Angaben zu Rule 144 und Rule 10b5-1.
- None.
- None.
Insights
TL;DR: Routine insider notice to sell a small number of vested shares; unlikely to be material to valuation.
The filing shows an officer or insider proposing to sell 5,643 shares valued at $1.51M, with an earlier sale of 6,105 shares in the prior three months. Against 83.1M shares outstanding, these transactions represent a de minimis ownership change. The shares were received via restricted stock vesting, indicating compensation-related disposition rather than capital raising. From a market-impact perspective, the size and frequency suggest routine liquidity management rather than a material signal about firm fundamentals.
TL;DR: Filing appears compliant with Rule 144 disclosure; no governance red flags evident from this notice alone.
The notice provides required broker details (Fidelity Brokerage Services), acquisition history, and a representation that no material nonpublic information is known. The presence of prior recent sales is disclosed, and the acquisition method (restricted stock vesting) is consistent with executive compensation practices. Absent additional context鈥攕uch as large concentrated disposals, sudden executive departures, or conflicting disclosure鈥攖his Form 144 is a standard insider sale notice and does not in itself indicate governance concerns.
Labcorp Holdings Inc. comunica, tramite un avviso interno, la proposta di vendita di 5,643 azioni ordinarie per un valore di mercato complessivo di $1,505,439.54, da eseguirsi tramite Fidelity Brokerage Services sulla NYSE con data di vendita approssimativa 08/11/2025. Le azioni sono state acquisite il 03/30/2023 mediante vesting di azioni ristrette come compenso. La pratica segnala inoltre che il venditore aveva precedentemente venduto 6,105 azioni il 05/12/2025 per proventi lordi di $1,518,496.65. Il numero totale di azioni ordinarie in circolazione dell'emittente 猫 riportato pari a 83,100,000. Con la firma, il venditore dichiara l'assenza di informazioni materiali avverse non divulgate e indica le dichiarazioni di conformit脿 relative alla Rule 144 e alla Rule 10b5-1.
Labcorp Holdings Inc. informa en un aviso de insider sobre la propuesta de venta de 5,643 acciones ordinarias por un valor de mercado agregado de $1,505,439.54, que se ejecutar铆a a trav茅s de Fidelity Brokerage Services en la NYSE con fecha aproximada de venta 08/11/2025. Las acciones fueron adquiridas el 03/30/2023 mediante vesting de acciones restringidas como compensaci贸n. La presentaci贸n tambi茅n muestra que el vendedor vendi贸 previamente 6,105 acciones el 05/12/2025 por ingresos brutos de $1,518,496.65. Las acciones ordinarias totales en circulaci贸n del emisor se reportan en 83,100,000. Al firmar, el vendedor declara que no existe informaci贸n material adversa no divulgada y se帽ala las declaraciones de cumplimiento relevantes a la Rule 144 y la Rule 10b5-1.
Labcorp Holdings Inc. 雮措秬鞛� 瓿奠嫓鞐� 霐半ゴ氅�, 齑� 鞁滉皜 鞎� $1,505,439.54 靸侂嫻鞚� 氤错喌欤� 5,643欤�毳� NYSE鞚� Fidelity Brokerage Services毳� 韱淀暣 08/11/2025搿� 鞓堨爼霅� 雽�霝奠爜鞚� 毵る弰鞚检棎 毵り皝頃� 鞓堨爼鞚措澕瓿� 氤搓碃頄堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� 03/30/2023鞐� 氤挫垬搿滌劀 鞝滍暅欤检嫕 氩犾姢韺�(restricted stock vesting)鞚� 韱淀暣 旆摑霅橃棃鞀惦媹雼�. 鞝滌稖靹滊鞐愲姅 霕愴暅 韺愲Г鞛愱皜 鞚挫爠鞐� 05/12/2025鞐� 6,105欤�毳� 毵り皝頃橃棳 齑濎垬鞚� $1,518,496.65鞚� 鞏混棃雼り碃 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氚滍枆須岇偓鞚� 齑� 氚滍枆 氤错喌欤� 靾橂姅 83,100,000鞙茧 氤搓碃霅╇媹雼�. 靹滊獏頃溂搿滌崹 韺愲Г鞛愲姅 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 歆勳垹頃橁碃 Rule 144 氚� Rule 10b5-1 甏�霠� 欷�靾� 歆勳垹鞚� 氇呾嫓頃╇媹雼�.
Labcorp Holdings Inc. signale, dans un avis d'initi茅, une vente propos茅e de 5,643 actions ordinaires pour une valeur marchande totale de $1,505,439.54, devant 锚tre ex茅cut茅e via Fidelity Brokerage Services 脿 la NYSE avec une date de vente approximative le 08/11/2025. Les actions ont 茅t茅 acquises le 03/30/2023 par vesting d'actions restreintes en tant que r茅mun茅ration. Le dossier indique 茅galement que le vendeur avait pr茅c茅demment c茅d茅 6,105 actions le 05/12/2025 pour un produit brut de $1,518,496.65. Le nombre total d'actions ordinaires en circulation de l'茅metteur est indiqu茅 脿 83,100,000. En signant, le vendeur d茅clare l'absence d'informations d茅favorables significatives non divulgu茅es et mentionne les d茅clarations de conformit茅 pertinentes 脿 la Rule 144 et 脿 la Rule 10b5-1.
Labcorp Holdings Inc. meldet in einer Insider-Mitteilung den geplanten Verkauf von 5,643 Stammaktien mit einem Gesamtmarktwert von $1,505,439.54, der 眉ber Fidelity Brokerage Services an der NYSE mit einem ungef盲hren Verkaufsdatum 08/11/2025 ausgef眉hrt werden soll. Die Aktien wurden am 03/30/2023 durch Restricted-Stock-Vesting als Verg眉tung erworben. Die Einreichung zeigt au脽erdem, dass der Verk盲ufer zuvor am 05/12/2025 6,105 Aktien f眉r Bruttoerl枚se von $1,518,496.65 verkauft hatte. Die insgesamt ausstehenden Stammaktien des Emittenten werden mit 83,100,000 angegeben. Mit seiner Unterschrift erkl盲rt der Verk盲ufer, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen, und verweist auf die Compliance-Angaben zu Rule 144 und Rule 10b5-1.
FAQ
Who is the filer selling Labcorp (LH) shares in this Form 144?
How many Labcorp (LH) shares are proposed for sale and what is their aggregate value?
When were the shares being sold originally acquired by the filer?
Did the filer sell any Labcorp (LH) shares in the past three months?
Through which broker and exchange will the proposed sale occur?
How large is the proposed sale relative to outstanding shares?
